Skip to main content

Table 3 Clinical and treatment data of children with HIV/AIDS α Treated in four ART ¥ Centers in Addis Ababa, Ethiopia followed from 2005-2011

From: Predictors of treatment failure and time to detection and switching in HIV-infected Ethiopian children receiving first line anti-retroviral therapy

Covariate Treatment failure (%) Treatment success (%) Crude hazard risk (95 CI**) Adjusted hazard risk (95 CI**)
Weight for Age     
 -Below 3rd centile€ 52(30.2) 120(69.8) 2.74(1.09-6.89) 0.54(0.13-2.25)
 >3rd < 97th centile 107(55.7) 85(44.3) 0.79(0.32-1.92) 0.41(0.11-1.55)
 Above 97th centile 6(13.6) 38(86.4) 1 1
Height for Age     
 Below 3rd centile 88(27) 239(63) 2.61(1.29-5.29) 3.25(1.00-10.58)
 >3rd < 97th centile 66(8.7) 697(91.3) 0.67(0.33-1.37) 1.05(0.33-3.33)
 Above 97th centile 10(22.2) 71(77.8) 1 1
Weight for Height     
 Below 3rd centile 15(14.3) 90(85.7) 1.10(0.61-1.98)  
 >3rd < 97th centile 41(16.7) 204(83.3) 1.33(0.89-1.98)  
 Above 97th centile 93(13.2) 614(86.8) 1  
WHO Clinical stage     
 Stages 1 or 2 58(12.7) 400(87.3) 0.84(0.59-1.18)  
 Stage 3 or 4 107(14.8) 617(85.2) 1  
Adherence to HAART     
 Optimal 162(14) 1006(86) 0.41(0.15-1.19)  
 Suboptimal 5(27.3) 13(72.7) 1  
Initial HAART Regimen     
 PI based £ 10(32.3) 21(67.7) 3.03(1.40-6.55) 1.05(0.33-3.89)
 NNRTI + NRTI 157(13.6) 998(86.4) 1 1
HAART drug substitution     
 Yes 29(23.6) 94(76.4) 2.07(1.31-3.25) 1.695(1.053-2.728)
 None 138(13) 925(87) 1 1
HAART Dosing preparation     
 Fixed 9(17.6) 42(82.4) 1.18(0.56-2.49)  
 Separate 109(15.4) 600(84.6) 1  
CD4 Count at initiation     
(cells/mm3)     
 <50 19(23.8) 61(76.2) 2.39(1.38-4.15) 2.30(1.28-4.14)
 ≥50 112(11.5) 859(88.5) 1 1
Chronic Diarrhea after initiation of ART¥     
 Yes 6(37.5) 10 (62.5) 3.76(1.35-1.50) 3.44 (1.37-8.62)
 None 161(13.8) 1009(86.2) 1 1
  1. **Confidence interval £-Started for infants who took prophylaxis; α Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome ¥ Antiretroviral therapy € Percentile.